Federal Circuit Ruling Potentially Upends Orange Book Patent Listing Requirements, Expert Analysis Reveals This ruling marks a pivotal moment in Hatch-Waxman practice, potentially altering how ...

Amneal Pharmaceuticals, Inc. offers strong growth prospects with undervalued stock, rising revenues, reduced debt, and key ...

Amneal Pharmaceuticals (AMRX) is experiencing significant financial growth by focusing on making generic drugs more affordable and accessible—a ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) will present at the Barclays 27th Annual Global Healthcare Conference on March, 12, 2025. Chirag Patel, Co-Chief ...

A group of 14 law and medical professors filed an amicus brief supporting Amneal’s response against rehearing, arguing the ruling would help remove improperly listed patents and accelerate generic ...

Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The company had revenue of $730.52 million for the quarter, compared to analyst estimates of ...

If you’re on the fence about investing in HUTCHMED (China) Limited, Amneal Pharmaceuticals or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before ...

Erectile dysfunction (ED) is a common condition, and many people find that it is treatable with Viagra — sometimes called the “little blue pill” — and its generic form, sildenafil.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates on ...

Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same period last year, the business earned $0.14 EPS.